SABCS 2023 HER2+ MBC

Trial in Progress: BRIDGET Trial of Tucatinib Plus Trastuzumab/Pertuzumab or Trastuzumab Emtansine After Isolated Intracranial Progression in HER2+ MBC

The ongoing BRIDGET (NCT05323955) trial is a single-arm, phase 2, multicenter study that is evaluating the addition of tucatinib to trastuzumab/pertuzumab or trastuzumab emtansine after local therapy in patients with HER2+ metastatic breast cancer (MBC) with isolated brain relapse or progression. Read More ›

Interstitial Lung Disease Incidence with Sequential Antibody–Drug Conjugate Use in MBC

SABCS 2023 HER2+ MBC

Findings of a small multi-institution retrospective study do not indicate a clear increased risk for interstitial lung disease with sequential treatment of antibody–drug conjugates in patients with metastatic breast cancer (MBC). Read More ›

Real-World Evidence of the Effect of Body Mass Index on Treatment Outcomes in MBC

SABCS 2023 HER2+ MBC

Findings of a retrospective single-institution study indicates that higher body mass index (BMI) was associated with better survival outcomes compared with lower BMI in patients with metastatic/recurrent breast cancer. Read More ›

Trial in Progress: Real-World Experience of Trastuzumab Deruxtecan in HER2+ and HER2-low Unresectable and/or MBC (DESTINY-Breast-RESPOND Trial)

SABCS 2023 HER2+ MBC

The DESTINY-Breast-RESPOND trial is a multicenter, prospective, observational study of trastuzumab deruxtecan that is evaluating the effectiveness and tolerability of trastuzumab deruxtecan in patients with HER2+ or HER2-low unresectable and/or metastatic breast cancer (MBC) in a real-world setting. Read More ›

Tolerability of Pertuzumab in Older Patients with HER2+ Breast Cancer

SABCS 2023 HER2+ MBC

Real-world evidence from a single-center experience showed that pertuzumab was well tolerated in older patients with HER2+ breast cancer in the real-world setting; however, a quarter of patients discontinued treatment due to toxicities. Read More ›

SABCS 2023 HER2+ MBC

Page 2 of 2